ArborMed is a biopharmaceutical company committed to the development and commercialization of therapeutics for diseases with high unmet medical needs and untapped market opportunities. With operations in South Korea and US, Arbormed utilizes resources efficiently to enable "Fast to Market" development of the pipeline and US market entry.

Arbomed is a new drug development company with a pipeline focused on rare and intractable diseases, including Wilson's disease, acute respiratory distress syndrome (ARDS), and Pendred syndrome. In addition to its headquarters in Gangnam, Seoul, and an R&D center in Seongnam, Gyeonggi Province, the company also has a subsidiary in San Francisco, USA, that is capable of conducting clinical trials and pursuing FDA approval.

Private

Biotech